The maker of healthcare products and toiletries said revenue grew 4% to $121.8 million, which was behind Wall Street expectations.
Domestic sales grew about 7% to $116.1 million, driven by the performance of Gold Bond, ACT, Icy Hot, Cortizone-10 and Selsun Blue products.
Meanwhile, the company continues to expect adjusted earnings of $4.80 to $4.90 per share for the fiscal year ending November 2009.
The consensus estimate is currently $4.50 per share, which has improved by a penny over the past 2 months.
CHTT, a Zacks #3 Rank (“Hold”) stock, is down about 1% today on extraordinarily high volume of approximately $1 million, compared to the average daily volume of about 252,000.